SNDX
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.
Syndax Pharmaceuticals, Inc. (SNDX) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (A-); its weakest is Momentum (D).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-15 | B- (3.0) | A- (3.9) | C- (2.0) | D (1.5) | C+ (2.6) | C+ (2.6) |
| 2026-11-08 | B- (3.0) | A- (3.9) | C- (2.0) | C- (1.9) | C+ (2.6) | C+ (2.7) |
| 2026-11-01 | B- (3.0) | A- (3.9) | C (2.3) | C+ (2.5) | C+ (2.7) | B- (2.9) |
| 2026-10-25 | B- (3.0) | A- (3.9) | C (2.2) | C- (2.0) | C+ (2.6) | C+ (2.7) |
| 2026-10-18 | B- (3.0) | A- (3.9) | C (2.2) | D+ (1.7) | C+ (2.6) | C+ (2.7) |